Cardio-kidney-metabolic complexity in patients with atrial fibrillation: an analysis from the prospective GLORIA-AF registry phase III

Atrial Fibrillation

Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis

J Am Coll Cardiol

Pabon MA, Filippatos G, Claggett BL, Miao MZ, Desai AS, Jhund PS, Henderson A, Brinker M, Schloemer P, Hofmeister L, Li L, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD, Vaduganathan M

doi: 10.1016/j.jacc.2025.03.429

Atrial Fibrillation

Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry

Clin Res Cardiol

Menichelli D, Gazzaniga G, Poli D, Palareti G, Antonucci E, Pani A, Pignatelli P, Pastori D, START2 Register Investigators

doi: 10.1007/s00392-025-02765-7

Atrial FibrillationHeart Failure

Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure: Insights from the NCDR Atrial Fibrillation Ablation Registry

Heart Rhythm

Yousuf O, Akar J, Tan Z, Alkalbani M, Tasneem H, Steinberg BA, Hsu JC, Atwater B, Yang E, Spertus J, Calkins H, Freeman JV

doi: 10.1016/j.hrthm.2025.06.048

Atrial Fibrillation

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

JAMA Cardiol

Alexander JH, Lydon EJ, Piccini JP, Viethen T, Oldgren J, Goodman SG, Steffel J, Russo AM, van Gelder IC, Ferdinand KC, Lopes RD, Mundl H, Benczur B, Gómez-Doblas JJ, Glikson M, Goudev A, Grove EL, Halvorsen S, Kiviniemi T, Martin AC, Sandhu RK, Vinereanu D, Rockhold FW, Caso V, Coppolecchia R, Patel MR

doi: 10.1001/jamacardio.2025.0277

Atrial FibrillationThrombosis and Stroke

Risk of ischemic stroke in sinus node dysfunction with and without atrial fibrillation: evidence for the presence of a left atrial myopathy in patients with isolated sinus node dysfunction - an analysis of the UK Biobank

Heart Rhythm

Virk SA, Ho WWH, Takeuchi F, Morris GM, Kistler PM, Kalman J

doi: 10.1016/j.hrthm.2025.04.055

Thrombosis and StrokeTherapy and Intervention

Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial

Lancet

Veltkamp R, Korompoki E, Harvey KH, Harvey ER, Fießler C, Malzahn U, Rücker V, Montaner J, Caso V, Sibon I, Ringleb P, Halse O, Hügen K, Ullmann S, Schuhmann C, Todd GP, Haas K, Palà E, Debette S, Lachaize M, D'Aoust T, Enzinger C, Ropele S, Fandler-Höfler S, Haidegger M, Wang Y, Wafa HA, Cancelloni V, Mosconi MG, Lip GYH, Lane DA, Haefeli WE, Foerster KI, Wurmbach VS, Nielsen PB, Hajjar K, Müller P, Poli S, Purrucker J, Laible M, D'Anna L, Silva Y, de Torres Chacon R, Martínez-Sánchez P, Boulanger M, Norrving B, Paré G, Wachter R, Ntaios G, Wolfe CDA, Heuschmann PU, PRESTIGE-AF Consortium

doi: 10.1016/S0140-6736(25)00333-2

Atrial Fibrillation

Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

Heart Rhythm

Boriani G, McIntyre WF, Ramasundarahettige C, Proietti M, Glotzer TV, Diemberger I, Nielsen JC, Essebag V, Granger CB, Sandhu RK, Benezet-Mazuecos J, Mabo P, Coutu B, Wong JA, Gold MR, Lopes RD, Healey JS, ARTESiA Investigators

doi: 10.1016/j.hrthm.2025.07.002

Atrial FibrillationTherapy and Intervention

Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial

JAMA Cardiol

Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Murphy SA, Hug B, Parkar S, Chen SA, Goodman SG, Joung B, Kiss RG, Wojakowski W, Weitz JI, Bloomfield D, Sabatine MS, Ruff CT

doi: 10.1001/jamacardio.2025.3393

Atrial Fibrillation

Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation - a Registry-based Multicenter Randomized Controlled Study

Circulation

Oldgren J, Hijazi Z, Arheden H, Björkenheim A, Frykman V, Janzon M, Ravn-Fischer A, Renlund H, Själander A, Åkerfeldt T, Wallentin L

doi: 10.1161/CIRCULATIONAHA.125.076725

Related content

Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis

Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry

Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure: Insights from the NCDR Atrial Fibrillation Ablation Registry

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

Risk of ischemic stroke in sinus node dysfunction with and without atrial fibrillation: evidence for the presence of a left atrial myopathy in patients with isolated sinus node dysfunction - an analysis of the UK Biobank

Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial

Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial

Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation - a Registry-based Multicenter Randomized Controlled Study